[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Buck Institute for Research on Aging\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":130},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,83,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100565720","targeting-aging-with-a-ketone-ester-for-function-in-frailty-100565720",false,"NCT06645847","Targeting Aging With a Ketone Ester for Function in Frailty","A Randomized, Double-blind, Placebo-controlled, Parallel Group, Pilot Study to Evaluate the Effect of a Ketone Ester on Muscle and Immune Function in Older Men and Women Who Are at Risk for Strength and Mobility Decline","TAKEOFF","Inclusion Criteria:\n\n1. Subject is greater than or equal to 65 years of age, inclusive at Screening.\n2. Passes the gait speed criteria at Screening.\n3. Minimum body weight of 50 kgs at Screening.\n4. Subject is willing and able to comply with all study procedures including randomization into any of the experimental groups, maintenance of habitual dietary intake, exercise and medication and supplement use, blood draws and the following prior to test visits: fasting (≥10 h; water only), no alcohol (≥ 10 h), no cannabis products (≥10 h) and no exercise (≥ 10 h).\n5. Subject understands the study procedures and can provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Subject is non ambulatory.\n2. Subject has a CSHA clinical frailty score \\> 5.\n3. Subject requires assistance with any activity of daily living, excluding continence.\n4. Subject lives in an institutional setting (skilled nursing facility or residential care facility for the elderly).\n5. Subject is a female who has not passed menopause.\n6. Subject is unable to converse in English (or Spanish, if available at the study site).\n7. Subject has been hospitalized within 30 days of Screening.\n8. Subject has any physical limitation that would prevent them from performing 1RM leg press based on Medical Officer judgement.\n9. Subject has an abnormal laboratory test result(s) of clinical importance at Screening, indicating unstable chronic disease of major organ dysfunction that requires urgent evaluation, at the discretion of the Medical Officer. One re-test will be allowed on a separate day prior to Visit 1, for subjects with abnormal laboratory test results. Additional clinical information may be gathered from the participant if needed to interpret the urgency of laboratory abnormalities (e.g. recent laboratory trends if an electrolyte is abnormal).\n10. Subject has uncontrolled hypercholesterolemia on screening labs.\n11. Subject has a history or presence of acute or uncontrolled and\u002For clinically active pulmonary (chronic obstructive pulmonary disease \\>= Gold 3), cardiac (e.g. \\>= New York Heart Association class III), hepatic (cirrhosis), renal (chronic kidney disease stage \\>= IIIb), endocrine (including type 1 diabetes), hematologic, immunologic, neurologic (e.g., Alzheimer's or Parkinson's diseases), psychiatric (including unstable depression and\u002For anxiety disorders) or biliary disorders. \"Uncontrolled\" and \"clinically active\" are per the judgement of the Medical Officer. Stable chronic disease is not an exclusion criterion unless specified. Chronic disease that is managed with the patient's physician per shared decision-making, even if sub optimally by typically recommended care, is not an exclusion criterion unless uncontrolled or clinically active.\n12. Subject has a clinically important gastrointestinal condition that would potentially interfere with the evaluation of the study beverage \\[e.g., inflammatory bowel disease, irritable bowel syndrome, chronic constipation, severe constipation (in the opinion of the Medical Officer), history of frequent diarrhea, history of surgery for weight loss, gastroparesis, systemic disease that might affect gut motility according to the Investigator, history of gastrointestinal ulcers or bleeding, history of pancreatitis, history of hiatal hernia, history of Barrett's esophagus, or history of esophageal cancer\\].\n13. Heavy drinking (For women, 8 or more drinks per week. For men, 15 or more drinks per week).\n14. Subject has a history of alcohol or substance abuse.\n15. Subject has been instructed not to consume alcohol for medical reasons.\n16. Subject has a known, clinically important allergy, intolerance, or sensitivity to any of the ingredients in the study beverages, including soy and milk protein.\n17. Subject has uncontrolled hypertension as defined by the blood pressure measured at Screening. For subjects with elevated blood pressure at Screening, they are allowed for the purpose of this criteria to submit home readings from three separate days, or to have a repeat reading taken at the study site on a separate day before Visit 1.\n18. Subject is undergoing treatment or active surveillance for cancer or has been diagnosed with cancer in the prior two years, except for non-melanoma skin cancer. Active surveillance is defined as regular imaging or laboratory tests at a frequency greater than annually. Cancer under long-term monitoring such as stable chronic lymphocytic leukemia need not be an exclusion, on the discretion of the Medical Officer.\n19. Immunosuppressive disorders, taking immunosuppressive medications (including oral prednisone \\>10mg\u002Fday and biological immunosuppressants), or receiving chemotherapy.\n20. Chronic antibiotic use (e.g. expected to be ongoing, regardless of frequency, throughout the study period).\n21. Subject has extreme dietary habits (e.g., intermittent fasting or time restricted eating, Atkins diet, vegan, very high protein\u002Flow carbohydrate or has used weight-loss medications (including over-the-counter medications and\u002For supplements) or programs within 30 days of Screening.\n22. Subject has followed a ketogenic diet or used ketone supplements (ketone salts or esters, and medium chain triglycerides) within 30 days of Screening.\n23. Subject has a condition the Medical Officer believes would interfere with their ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the subject at undue risk.\n24. Subject works nights or shifts that means it is not possible to maintain a consistent meal schedule during the study.",true,"ALL","65 Years",{"count":21,"type":22},180,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to find out if a food supplement that contains a naturally occurring substance, ketones, can help to improve strength and general wellness in adults at, or over the age of 65 years who are experiencing a slight decline in their physical function.\n\nParticipation will involve a screening visit and 4 additional study visits over the course of 20 weeks. After being assessed for eligibility, study participants will be sorted into two groups at random and consume either a ketone or placebo supplement at home every day for 20 weeks. Both study products can cause gastro-intestinal side effects in some individuals. At all study visits, subjects will provide blood samples. At three study visits, subjects will be asked to complete physical performance tests, provide blood, stool and urine samples. They will also complete questionnaires during three study visits to assess physical function, markers of inflammation, and other aspects of general well-being.\n\nThe study enrolls at three sites across the United States, in California (Buck Institute), Ohio (Ohio State University), and Connecticut (University of Connecticut). The study is coordinated by the San Francisco Coordinating Center (California Pacific Medical Center).",[28,29,30,31],"Frail Elderly","Aging","Immune Function","Muscle Function",[33,34],"ketone ester","exogenous ketone","RECRUITING","2026-03-12",{"date":38,"type":39},"2026-03-13","ACTUAL",{"date":41,"type":39},"2025-02-05",{"date":43,"type":22},"2028-04-01",{"name":45,"class":46},"Buck Institute for Research on Aging","OTHER",3,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":19,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100578589","glylo-supplement-pilot-trial-on-glycation-and-aging-in-postmenopausal-women-100578589","NCT06813261","GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women","A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Trial Investigating the Impact of a Glycation Lowering (GLYLO) Supplement on Geroscience Outcomes in Postmenopausal Women","GRACE","Inclusion Criteria:\n\n1. Adults identified as female at birth with ovaries present (self-report)\n2. Post menopause \\>1y since last menses (self-report)\n3. Aged 45 - 65 y\n4. Anthropometric criteria (either of the following must be met):\n\n   * BMI ≥ 25 kg\u002Fm², based on self-reported weight and height\n   * OR Waist circumference ≥88 cm, based on self-measured values. Participants may provide average home weight measurements over two consecutive days if their BMI at the screening visit is slightly below 25 kg\u002Fm².\n5. HbA1c 5.5- 6.4% (screening measurement)\n6. Able to read and speak English well enough to provide informed consent and understand instructions.\n7. Able to attend in-person visits at The Buck Institute\n\nExclusion Criteria:\n\n1. Surgical menopause (self-report)\n2. Hysterectomy and\u002For ovariectomy (self-report)\n3. Receiving systematic hormone replacement therapy (HRT) (self-report). Use of local vaginal estrogen therapy (e.g., estrogen creams, vaginal tablets, or estrogen rings such as Estring) is permitted.\n4. Currently prescribed or received weight loss medications within the past 6 months or currently enrolled in a defined weight loss program. Weight must be stable (\\> 4%) within the last 3 months.\n5. Regular use of GLYLO, or regular use of a supplement containing any of the ingredients in GLYLO, within the last 3 months.\n6. Diabetes, T1DM or T2DM (self-report and screening tests): Treatment with any hypoglycemic agents (self-report), fasting glucose \\>125 mg\u002FdL (screening test; may reassess once), current use of hypoglycemic drugs for non-diabetic reasons (self-report).\n7. Elevated blood pressure readings (screening test): Resting Systolic Blood Pressure (SBP) ≥180 mmHg or resting Diastolic Blood Pressure (DBP) ≥100 mmHg. If a participant's blood pressure is elevated at the screening visit but not consistent with this threshold, they may provide home blood pressure readings (twice daily for two consecutive days) for the study team to evaluate eligibility.\n8. Psychotropic and\u002For other medications known to significantly impact weight unless on a stable dose for ≥ 6 months (self-report).\n9. Liver enzyme tests (alanine transaminase, aspartate transaminase) (screening test): \\>2 times the laboratory upper limit of normal. Reassessment during screening may be allowed under some conditions (e.g., recent use of acetaminophen).\n10. Immunosuppressive disorders, taking immunosuppressive medications (including oral prednisone \\>10mg\u002Fday and biological immunosuppressants), or receiving chemotherapy.\n11. Active gastrointestinal bleeding, or active bleeding diathesis (or resolved within 6 months prior to randomization) (self-report)\n12. Active peptic ulcer disease (or resolved within 6 months prior to randomization) (self-report)\n13. Active malignancy (or resolved within 6 months prior to randomization), except non-melanoma skin cancer not undergoing treatment (self-report).\n14. Active infection (or resolved within 1 month prior to randomization) (self-report)\n15. Allergy or hypersensitivity to any component of the supplement (self-report)\n16. History of hyperthyroidism or thyroid cancer(self-report), current abnormal thyroid function (blood test at screening).\n17. Cognitive status: Unable to provide informed consent to participate in and safely complete the protocol, as based on the judgment of the investigators (screening visit)\n18. Psychiatric status: any condition that might affect the ability to comply with the protocol in the opinion of the Clinical Investigator or Medical Officer (screening visit)\n19. Active eating disorders (self-report).\n20. Active diagnosis of Gout (self-report)\n21. Any change to prescription medications within 3 months prior to randomization that are judged by the study physician to impact the results of the study (self-report)\n22. No overnight hospitalization within 1 month prior to randomization (self-report)\n23. The presence of a condition or abnormality that in the opinion of the Investigator or Medical Officer would compromise the safety of the patient or the quality of the data","FEMALE","45 Years",{"count":59,"type":22},30,[25],"The aim of this study is to assess the effectiveness of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. Specifically, the study seeks to evaluate whether GLYLO can reduce advanced glycation end products (AGEs) levels, which are harmful compounds formed when sugar attaches to proteins or fats in the body and can contribute to aging and disease. The primary outcome of the study is to determine if GLYLO reduces AGEs, enhances metabolic and hormonal health, and mitigates age-related functional decline.\n\nThis study includes one screening visit and three testing visits over a 6-month period. After eligibility is confirmed, participants will be randomly assigned to one of two groups to take either GLYLO (two capsules daily) or a placebo at home for 24 weeks. Participants will provide blood samples at every visit. During the three testing visits, they will complete physical performance and cognitive function tests, provide both blood and urine samples, and fill out quality of life and 24-hour dietary intake questionnaires. The dietary intake questionnaires will be completed only twice i.e. at the baseline visit and again at the final 6-month visit.",[63,64,65],"Postmenopause","Metabolism","Geroscience",[67,68,69,70,71,72,73],"Dietary supplement","Healthy aging","Women's health","Hormones","Advanced glycation end products (AGEs)","Glycation stress","Metabolic stress","2025-09-04",{"date":76,"type":39},"2025-09-08",{"date":78,"type":39},"2025-04-01",{"date":80,"type":22},"2026-06-30",{"name":45,"class":46},1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":17,"sex":18,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":82},"100601199","temporal-investigation-of-multimodal-elements-100601199","NCT07107386","Temporal Investigation of Multimodal Elements","An Observational, Longitudinal Study to Characterize the Dynamic Structure of Molecular and Digital Health Data in Healthy Older Adults","TIME","Inclusion Criteria:\n\n* Healthy adults aged 55 years or older.\n* Own a smartphone capable of running study-specific apps.\n* Willing and able to attend in-person visits at the Buck Institute in Novato, CA.\n* Reside in the Pacific or Mountain Time Zones.\n* Able to speak, read, and write English.\n* Willing to wear study devices continuously and allow researchers access to all data.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Hospitalization within the last 3 months.\n* Needing assistance with daily living activities.\n* Working night or irregular shifts.\n* Certain musculoskeletal, pulmonary, or cardiovascular conditions.\n* Uncontrolled high blood pressure (BP \\> 180\u002F100 mmHg).\n* Bleeding disorders, anemia requiring treatment, or recent blood donation.\n* Poor vein access.\n* Unstable health conditions.\n* Chronic antibiotic use.\n* Certain psychiatric disorders.\n* Use of excluded medications, supplements, or products, including certain antibiotics or frequent sleep aids.","55 Years",{"count":93,"type":22},120,"OBSERVATIONAL","The TIME Study is a research project aiming to understand the body's natural rhythms. The goal is to see how daily and weekly changes in our bodies-from what's happening at a molecular level to data from wearable devices-are connected.\n\nWhat is the study about? This study is trying to create a detailed map of how a person's body changes over time. By looking at information from blood, urine, and other samples, as well as data from smartwatches and other devices, researchers want to learn how our bodies' natural cycles work in healthy older adults. The long-term goal is to use this knowledge to help develop more personalized healthcare in the future.\n\nWho can participate? The study is looking for healthy adults, age 55 or older, who have a smartphone and are able to travel to the Buck Institute in Novato, California, for study visits.\n\nParticipants will be asked to:\n\nAttend weekly visits over 11 weeks to provide blood and other samples.\n\nWear health-tracking devices like a smart ring and watch.\n\nUse a smartphone app to answer questions about their daily routines.\n\nComplete two \"challenge\" tests, including drinking a glucose solution and exercising on a stationary bicycle.\n\nReturn for follow-up visits after 6 and 12 months.\n\nAre there any risks or benefits? Benefits: There are no direct health benefits for participants. However, the information gained will help scientists create better diagnostic tools and treatments for future generations.\n\nRisks: The main risks are minor discomfort from things like blood draws or skin irritation from the wearable devices. All personal information and data are kept private and secure.",[97],"Health","2025-08-12",{"date":100,"type":39},"2025-08-15",{"date":102,"type":39},"2025-06-15",{"date":104,"type":22},"2028-06",{"name":45,"class":46},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":82},"100557605","molecular-optimization-via-exercise-move-100557605","NCT06540287","Molecular Optimization Via Exercise (MOVE)","An Observational Study of Aging Biomarkers in Older Elite Athletes Compared to Non-exercising Healthy Older Adults.","1. Willing and able to provide consent to take part in the MOVE-1 Main Study.\n2. Willing and able to attend study visits and comply with all procedures of study data collection visits.\n3. Able to read and speak English well enough to provide informed consent and understand instructions.\n4. Healthy adults between the age of 65 - 80 y.\n5. BMI \\>19 to \\\u003C 35 kg\u002Fm2\n6. No personal plans (i.e., vacations or medical procedures) during the expected study period (Screening, Test Visit 1, 2 and Sample Collection Visit).\n7. Older Elite Athletes (OEA):\n\n   • Evidence of current physical activity at an elite level for their age, as well as a consistent history of high activity level. This is assessed by interview, review of training data and\u002For competition results, and by review of the VO2 max data obtained during Testing Visit 1.\n8. Healthy Older Adults (HOA):\n\n   * Sedentary, defined as self-reporting no more than 1 day per week, lasting no more than 60 minutes, of regular (structured) endurance exercise \\[e.g., brisk walking, jogging, running, cycling, elliptical, or swimming activity that results in feelings of increased heart rate, rapid breathing, and\u002For sweating\\] or resistance exercise (resulting in muscular fatigue) in the past year.\n   * Persons bicycling as a mode of transportation to and from work \\>1 day\u002Fweek etc. are not considered sedentary.\n   * Leisure walkers are included unless they meet the heart rate, breathing, and sweating criteria noted above.\n   * Does not have a physically active job, no history of physically active job (i.e., postal worker, fire officer\n   * No history of consistent high activity level (meeting above criteria) in the last 25 y.\n\n3.2.2. Main Study Exclusion Criteria\n\n1. Subject requires assistance with any activity of daily living, excluding continence.\n2. Subject lives in an institutional setting (skilled nursing facility or residential care facility for the elderly).\n3. Abnormal bleeding or coagulopathy (self-report): History of a bleeding disorder, wound healing disorder or clotting abnormality.\n4. Female participants must be post-menopause.\n5. Musculoskeletal conditions that would prevent completion of any required exercise testing.\n6. Elevated blood pressure readings (screening test): Resting Systolic Blood Pressure (SBP) ≥150 mmHg or resting Diastolic Blood Pressure (DBP) ≥90 mmHg\n7. Diabetes (self-report and screening tests): Treatment with any hypoglycemic agents (self-report), fasting glucose \\>125 mg\u002FdL (screening test; may reassess once), use of hypoglycemic drugs for non-diabetic reasons (self-report).\n8. Pulmonary (self-report): Clinical diagnosis of any chronic pulmonary disease that limits exercise capacity.\n9. Cardiovascular (self-report, screening test, and clinician judgement): Congestive heart failure, coronary artery disease, significant valvular disease, congenital heart disease, serious arrhythmia, pulmonary embolism, stroke, or symptomatic peripheral artery disease (self-report, screening test). Specific criteria used to determine whether a volunteer can undergo the screening CPET follow the American Heart Association (AHA) Criteria \\[6\\]. Inability to complete the CPET. Reassessment of the CPET may be allowed under some circumstances (e.g., test was not a maximal effort)\n10. Abnormal blood lipid profile (screening test): Fasting triglycerides \\>500 mg\u002FdL. Low-density lipoprotein cholesterol (LDL-C) \\>190 mg\u002FdL\n11. Cancer (self-report): History of cancer treatment (other than non-melanoma skin cancer, or chronic lymphocytic leukemia) and not \"cancer-free \"for at least 2 years. Anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months.\n12. Chronic active or latent infection (self-report): Active or latent infections requiring chronic antibiotic or anti-viral treatment, excluding herpes simplex virus. Chronic active infection whether on chronic antimicrobials or not. Human Immunodeficiency Virus. Active hepatitis B or C undergoing antiviral therapy. Individuals successfully treated for hepatitis C and virologically negative for at least 6 months are not excluded.\n13. Liver enzyme tests (alanine transaminase, aspartate transaminase) (screening test): \\>2 times the laboratory upper limit of normal. Reassessment during screening may be allowed under some conditions (e.g., recent use of acetaminophen). Individuals may be referred to their PCP for evaluation; any medication change must be stable for ≥3 months prior to retesting.\n14. Chronic renal insufficiency (screening test): Estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m2 from serum creatinine (mg\u002FdL) by the Chronic Kidney Disease Epidemiology Collaboration equation. Subjects must be able to produce urine. Reassessment may be allowed under some conditions (e.g., questionable hydration status or other acute renal insult)\n15. Hematocrit (screening test): Hematocrit \\>3 points outside of the local normal laboratory ranges for women and men. Reassessment may be allowed under certain conditions. Individuals may be referred to their PCP for evaluation; any medication change must be stable for ≥3 months prior to retesting.\n16. Blood donation (self-report): Whole blood donation in the last 3 months or plans for blood donation during the entire protocol period. Platelet or plasma donation in the last week or plans for platelet or plasma donation during the entire protocol period.\n17. Autoimmune disorders (self-report): Individuals receiving any active systemic treatment (including immunosuppressants and\u002For monoclonal antibodies) within the last 6 months.\n18. Alcohol consumption (self-report): Current consumption of more than 7 drinks per week for women More than 14 drinks per week for men. History of binge drinking in the past five years (≥5 drinks for males or ≥4 drinks for females in a 2-hour period more than once per month)\n19. Tobacco (self-report): Current smokers: any tobacco or e-cigarette\u002Fe-nicotine products. Former smokers: Stopped smoking \\\u003C10 years at time of screening for those with a ≥20 pack-year smoking history. Stopped smoking \\\u003C5 years at time screening for those with a \\\u003C20 pack-year smoking history.\n20. Recreational drug use (self-report): Self-reported use ≥3 days\u002Fweek in any form\n21. Shift workers (self-report): Night shift work in the last 6 months. Planning night shift work during the study period.\n22. Cognitive status (screening): Unable to give consent to participate in and safely complete the protocol, as based on the judgement of the investigators.\n23. Psychiatric illness (self-report and screening test): Hospitalization for any psychiatric condition within one year (self-report).\n24. Weight change (self-report): Weight change (intentional or not) over the last 2 months of \\>5% of body weight. Plan to lose or gain weight during the study\n25. Lidocaine or other local anesthetic allergy (self-report): Known allergy to lidocaine or other local anesthetic\n26. COVID-19 infection: Individuals who tested positive for COVID-19 but were not hospitalized must be symptom free, at least 14 days (without a negative antigen test) or symptom-free at least 7 days with a negative antigen test on the day of the study visit. A PCR test can be used if antigen tests are not available.\n27. Other (clinician judgement): Genetic metabolic disorders that could affect metabolomic results (e.g., phenylketonuria). Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric, metabolic, or other conditions that, in the opinion of the local clinician, would preclude participation and successful completion of the protocol. Any other illnesses that, in the opinion of the local clinician, would negatively impact or mitigate participation in and completion of the protocol.","80 Years",{"count":115,"type":22},80,"This study is to investigate characteristics of muscle, blood, and urine samples from older adults (ages 65-80) who are either sedentary or athletes performing at an elite level for their age. This observational study will include bio-specimen collection, as well as physical and cognitive function testing and body composition.",[29],[119,120,121],"Biomarkers","Healthy older adults","Older elite athletes","2024-10-04",{"date":124,"type":39},"2024-10-08",{"date":126,"type":39},"2024-09-19",{"date":128,"type":22},"2027-05",{"name":45,"class":46},""]